Anastasia M Rivkin

Summary

Affiliation: Long Island University
Country: USA

Publications

  1. ncbi request reprint Chronic hepatitis B: current and future treatment options
    Anastasia Rivkina
    Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA
    Pharmacotherapy 22:721-37. 2002
  2. ncbi request reprint Infliximab in graft-versus-host disease
    Anastasia M Rivkina
    Yale New Haven Hospital YNHH, New Haven, CT, USA
    Am J Health Syst Pharm 59:1271-5. 2002
  3. ncbi request reprint Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review
    Anastasia Rivkin
    Department of Clinical Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201, USA
    Clin Ther 25:1952-74. 2003
  4. ncbi request reprint Adefovir dipivoxil in the treatment of chronic hepatitis B
    Anastasia M Rivkin
    Clinical Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY, USA
    Ann Pharmacother 38:625-33. 2004
  5. ncbi request reprint Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus
    Anastasia M Rivkin
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    Pharmacotherapy 25:862-75. 2005

Collaborators

  • Anastasia M Rivkina
  • Anastasia Rivkina
  • Lisa S Stump
  • Sergey Rybalov

Detail Information

Publications5

  1. ncbi request reprint Chronic hepatitis B: current and future treatment options
    Anastasia Rivkina
    Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA
    Pharmacotherapy 22:721-37. 2002
    ..Therapeutic options for managing hepatitis infection after liver transplantation are also evolving. These include hepatitis B immunoglobulin and nucleoside analogues...
  2. ncbi request reprint Infliximab in graft-versus-host disease
    Anastasia M Rivkina
    Yale New Haven Hospital YNHH, New Haven, CT, USA
    Am J Health Syst Pharm 59:1271-5. 2002
    ..Authors should report serious adverse drug reactions to the FDA medical products reporting program (MedWatch). Such reporting will not jeopardize the chances that AJHP will publish manuscripts on the same drug reactions...
  3. ncbi request reprint Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review
    Anastasia Rivkin
    Department of Clinical Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201, USA
    Clin Ther 25:1952-74. 2003
    ..The physiologic actions of tegaserod relate to its ability to stimulate gastric and intestinal motility...
  4. ncbi request reprint Adefovir dipivoxil in the treatment of chronic hepatitis B
    Anastasia M Rivkin
    Clinical Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, NY, USA
    Ann Pharmacother 38:625-33. 2004
    ..To evaluate properties of the new acyclic nucleotide analog adefovir dipivoxil in the treatment of chronic hepatitis B (CHB)...
  5. ncbi request reprint Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus
    Anastasia M Rivkin
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
    Pharmacotherapy 25:862-75. 2005
    ..Future studies should address several issues: when to start epoetin alfa treatment, the duration of treatment, the drug's optimal dosage, its effects on end-of-treatment and sustained virologic response rates, and a cost analyses...